Korsana emerges with $175m to combat neurodegenerative diseases

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Paragon’s latest venture targets Alzheimer’s via delivery platform designed to cross the blood-brain barrier.

US biotech Korsana Biosciences has emerged from stealth with $175 million in funding and a focus on developing next-generation biologics designed to reach the brain more effectively and improve the treatment of neurodegenerative diseases. The Waltham, Massachusetts-based company is the sixth biotech to emerge from the stable of venture creator Paragon Therapeutics, and is initially targeting Alzheimer’s disease with its lead antibody program, supported by a proprietary platform designed to overcome long-standing drug delivery challenges associated with the blood-brain barrier.

Korsana’s strategy is built on a transferrin receptor-based antibody “shuttle” technology designed to improve delivery of large-molecule drugs across the blood-brain barrier. Crossing this barrier has historically been one of the most significant obstacles in developing therapies for central nervous system disorders, as many biologic drugs fail to reach sufficient concentrations in brain tissue. The company says its approach combines clinically validated transferrin receptor biology with a therapeutic antibody modification technique called “Fc engineering” to enhance brain penetration.

Korsana’s lead candidate, KRSA-028, is a monoclonal antibody targeting amyloid beta, a protein long implicated in Alzheimer’s disease. The therapy selectively binds forms of amyloid beta enriched in plaques and is designed to increase plaque clearance while reducing the risk of amyloid-related imaging abnormalities and other adverse events that have complicated first-generation treatments. Unlike currently marketed amyloid-targeting therapies that often require frequent intravenous infusions and intensive monitoring, KRSA-028 is being developed as a low-volume subcutaneous injection, an approach intended to ease treatment logistics for patients and caregivers.

“Only two disease-modifying therapies have been approved to treat Alzheimer’s, and both carry safety warnings, offer only modest efficacy, and impose a high burden of care,” said Korsana CEO Dr Jonathan Violin. “Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s.”

Beyond Alzheimer’s disease, Korsana is building a broader pipeline of candidates aimed at other neurodegenerative conditions, though specific targets remain undisclosed. The company’s broader thesis rests on the idea that improving delivery into the brain could unlock new opportunities for biologics across multiple neurological indications, where traditional therapies have struggled to achieve sufficient exposure at sites of disease.

Korsana’s war chest includes a $25 million seed round led by Fairmount and Venrock Healthcare Capital Partners, followed by a $150 million Series A financing completed in September 2025, co-led by Wellington Management and TCGX.

“We believe Korsana is well positioned to overcome the limitations of not just first-generation Alzheimer’s therapies, but also of earlier shuttle technologies,” said Venrock partner Dr Andrew Gottesdiener. “Leveraging a well-established regulatory pathway, Korsana is advancing the next generation of therapies for Alzheimer’s disease and other neurodegenerative disorders, with a clear path to creating value for patients.”

The company’s financing is expected to fund its operations into 2028, targeting mid-2027 for initial Phase1 data from healthy volunteers, including evidence of central nervous system penetration, followed by early proof-of-concept results in Alzheimer’s patients by the end of that year.

Photo of Jonathan Violin, CEO, courtesy of Korsana Biosciences.

LTUI: 3619

Korsana Biosciences

Longevity level(s):

  • Level 5: Aging disease management
    Therapeutic interventions that manage the symptoms of diagnosed aging diseases (i.e. current mainstream healthcare) and biotechnology companies focused on developing drugs to treat age-related diseases.
  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Korsana Biosciences is a clinical-stage biopharmaceutical company focused on developing precision-engineered therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary Therapeutic Targeting (THETA™) platform, a blood-brain barrier-penetrant shuttle technology designed to enhance central nervous system exposure of investigational therapies. Korsana's lead program, KRSA-028, is a next-generation monoclonal antibody targeting amyloid beta, developed in partnership with Paragon Therapeutics. The company's mission centers on reducing the burden of neurodegenerative diseases by delivering best-in-class therapeutics that overcome limitations of earlier drug delivery approaches.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE